In the future, developing therapeutic regimens that target TAMs, such as interfering with TAM-related pathways, reducing infiltration of TAMs, and reprogramming the macrophage phenotype, could enhance the anti-tumor effect of EGFR-TKIs. The gene discussed is EGFR; the disease is neoplasm.